Activation of tumor specific T-lymphocytes caused by radio frequency ablation of liver tumors ȁ A patient study

Wissniowski, TT; Haensler, J; Schuppan, Detlef; Neureiter, Daniel; Frieser, M.; Schaber, S.; Hahn, EG; Strobel, D

doi:10.1016/s0016-5085(03)83899-4

Cited by 86 publications

(141 citation statements)

References 0 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…However, little is known regarding the induction of antitumor immune responses following RFA. Preliminary studies in pig and rabbit revealed an influx of immune cells in the periphery of the coagulation area directly after RFA, together with an increased T-cell proliferation (27,28).…”

Section: Discussionmentioning

confidence: 99%

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

Brok

Sutmuller²,

Voort³

et al. 2004

Cancer Research

382

284

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

Brok

Sutmuller²,

Voort³

et al. 2004

Cancer Research

382

284

View full text Add to dashboard Cite

“…It remained unclear if the observed T cell response was merely directed to papilloma viral antigens that are derived from the VX2 hepatoma compared to a tumorspecific T-cell reaction. However, we could recently demonstrate a marked tumor-specific peripherial T cell response in RFA-treated vs untreated rabbits with the VX2 hepatoma [5] . The aim of the present study was to demonstrate if an antitumor T cell response is also inducible in patients who are subjected to RFA.…”

Section: Introductionmentioning

confidence: 87%

Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases

Hänsler

Wissniowski²,

Schuppan³

et al. 2006

WJG

116

View full text Add to dashboard Cite

to 0.109 (± 0.005) for CD4 + and 0.11 (± 0.012) for CD8 + T cells against HCC, and to 0.115 (± 0.031) for CD4 + and 0.15 (± 0.02) for CD8 + cells for colorectal metastases (P < 0.0001). No increased SI was observed with nonmalignant tumor tissue at all time points. Before RFA cytolytic activity against the respective cancer cells was low with 2.62 (± 0.37) relative luminescence units (RLU), but rose more than 100 fold 4 and 8 wk after RFA. Spontaneous release was < 2% of maximum release in all experiments. CONCLUSION:Patients with primary and secondary tumors of the liver show a significant tumor-specific cytotoxic T-cell stimulation with a dramatically increased tumor specific cytolytic activity of CD8 + T cells after RFA. INTRODUCTIONOpen surgery is still the gold standard for the treatment of hepatocellular carcinoma (HCC) and liver metastases of colorectal cancer. However, more than 75% of these patients are non-resectable for various reasons, such as size and location of the tumor. Radio-frequency thermal ablation (RFA) is a common therapy option for unresectable liver tumors. Thus it was shown that RFA and laserinduced thermo-therapy (LiTT) can achieve survival times comparable to surgery in selected patients [1][2][3] . RFA uses a radio-frequency current to induce coagulation necrosis which results in a local thermal necrosis accompanied by Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases www

show abstract

“…[7,8] Together the data shows that inflammation is a common feature seen in HCC and this tumor can elicit an immune response.…”

Section: [4]mentioning

confidence: 77%

Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

Feun¹,

Li²,

Wangpaichitr³

et al. 2017

View full text Add to dashboard Cite

Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Multiple randomized trials, which compare the new agent to sorafenib as either first line or second line therapy, have been negative, showing no improved clinical benefit. Recently, in a large phase III randomized trial, regorafenib has shown superiority to placebo as a second line treatment for HCC. However, this drug has multiple side effects and is not well tolerated by many patients. The clinical benefit is also modest. Clearly, new approaches to treat advanced HCC are still needed. There is data showing that HCC is immunogenic and the immune system can be stimulated to attack these cancer cells. This article will briefly review immunotherapy as a promising treatment for HCC. Key words:Immunotherapy, hepatocellular carcinoma, sorafenib, new approaches ABSTRACTArticle history:

show abstract

Activation of tumor specific T-lymphocytes caused by radio frequency ablation of liver tumors ȁ A patient study

Cited by 86 publications

References 0 publications

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity

Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases

Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

Contact Info

Product

Resources

About